Modality
Small Molecule
MOA
ALKi
Target
CD20
Pathway
Cell Cycle
Heart Failure
Development Pipeline
Preclinical
~Sep 2018
→ ~Dec 2019
Phase 1
~Mar 2020
→ ~Jun 2021
Phase 2
Sep 2021
→ Sep 2027
Phase 2Current
NCT03961041
1,006 pts·Heart Failure
2021-09→2027-09·Recruiting
1,006 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-09-081.4y awayPh3 Readout· Heart Failure
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2/3
Recruit…
Catalysts
Ph3 Readout
2027-09-08 · 1.4y away
Heart Failure
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03961041 | Phase 2/3 | Heart Failure | Recruiting | 1006 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA |